Assessment of Molecular Measures in Non-FXTAS Male Premutation Carriers

Approximately 30–40% of male and 8–16% of female carriers of the Fragile X premutation will develop a neurodegenerative movement disorder characterized by intentional tremor, gait ataxia, autonomic dysfunction, cognitive decline, and Parkinsonism during their lifetime. At the molecular level, premut...

Full description

Bibliographic Details
Main Authors: Reem R. Al Olaby, Hiu-Tung Tang, Blythe Durbin-Johnson, Andrea Schneider, David Hessl, Susan M. Rivera, Flora Tassone
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-08-01
Series:Frontiers in Genetics
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fgene.2018.00302/full
id doaj-0908f581414d4d4285a756f52e88a12f
record_format Article
spelling doaj-0908f581414d4d4285a756f52e88a12f2020-11-24T23:39:28ZengFrontiers Media S.A.Frontiers in Genetics1664-80212018-08-01910.3389/fgene.2018.00302354250Assessment of Molecular Measures in Non-FXTAS Male Premutation CarriersReem R. Al Olaby0Hiu-Tung Tang1Blythe Durbin-Johnson2Andrea Schneider3Andrea Schneider4David Hessl5David Hessl6Susan M. Rivera7Susan M. Rivera8Flora Tassone9Flora Tassone10Department of Biochemistry and Molecular Medicine, UC Davis Medical Center, University of California, Davis, Davis, CA, United StatesDepartment of Biochemistry and Molecular Medicine, UC Davis Medical Center, University of California, Davis, Davis, CA, United StatesDepartment of Biostatistics, University of California, Davis, Davis, CA, United StatesDepartment of Pediatrics, UC Davis Medical Center, University of California, Davis, Davis, CA, United StatesMIND Institute, UC Davis Medical Center, Sacramento, CA, United StatesMIND Institute, UC Davis Medical Center, Sacramento, CA, United StatesDepartment of Psychiatry and Behavioral Sciences, UC Davis Medical Center, University of California, Davis, Davis, CA, United StatesDepartment of Psychiatry and Behavioral Sciences, UC Davis Medical Center, University of California, Davis, Davis, CA, United StatesNeurocognitive Development Lab, Department of Psychology, UC Davis Center for Mind and Brain, University of California, Davis, Davis, CA, United StatesDepartment of Biochemistry and Molecular Medicine, UC Davis Medical Center, University of California, Davis, Davis, CA, United StatesDepartment of Pediatrics, UC Davis Medical Center, University of California, Davis, Davis, CA, United StatesApproximately 30–40% of male and 8–16% of female carriers of the Fragile X premutation will develop a neurodegenerative movement disorder characterized by intentional tremor, gait ataxia, autonomic dysfunction, cognitive decline, and Parkinsonism during their lifetime. At the molecular level, premutation carriers have increased expression levels of the FMR1 and the antisense FMR1 (ASFMR1) mRNAs. Both genes undergo alternative splicing giving rise to a number of different transcripts. Alteration in the alternative splicing process might be associated with FXTAS. In this study, we have investigated the correlation between objective measures of movement (balance and tremor using the CATSYS battery) and the expression of both the FMR1 and the ASFMR1 genes. In addition, we investigated whether their expression level and that of the ASFMR1 131 bp splice isoform could distinguish between premutation carriers with FXTAS and non-FXTAS premutation carriers. Confirming previous findings, the expression levels of transcripts at the FMR1 locus positively correlated with the CGG repeat number and significantly differentiated the premutation carriers from the control groups. Furthermore, premutation carriers with and without FXTAS, showed a significant difference in the expression level of the ASFMR1 131 bp splice isoform when compared to age and gender matched controls. However, there was no significant difference in the ASFMR1 131 bp splice isoform expression level when comparing premutation carriers with and without FXTAS. Finally, our results indicate significant group differences in CATSYS dominant hand reaction time and postural sway with eyes closed in premutation carriers without FXTAS compared to controls. In addition, a significant inverse association between the tremor intensity and the expression level of ASFMR1 131 bp splice isoform in premutation carriers compared to controls, was observed, suggesting a potential role in the pathogenesis of FXTAS.https://www.frontiersin.org/article/10.3389/fgene.2018.00302/fullFMR1ASFMR1transcriptionpremutationFXTASCATSYS
collection DOAJ
language English
format Article
sources DOAJ
author Reem R. Al Olaby
Hiu-Tung Tang
Blythe Durbin-Johnson
Andrea Schneider
Andrea Schneider
David Hessl
David Hessl
Susan M. Rivera
Susan M. Rivera
Flora Tassone
Flora Tassone
spellingShingle Reem R. Al Olaby
Hiu-Tung Tang
Blythe Durbin-Johnson
Andrea Schneider
Andrea Schneider
David Hessl
David Hessl
Susan M. Rivera
Susan M. Rivera
Flora Tassone
Flora Tassone
Assessment of Molecular Measures in Non-FXTAS Male Premutation Carriers
Frontiers in Genetics
FMR1
ASFMR1
transcription
premutation
FXTAS
CATSYS
author_facet Reem R. Al Olaby
Hiu-Tung Tang
Blythe Durbin-Johnson
Andrea Schneider
Andrea Schneider
David Hessl
David Hessl
Susan M. Rivera
Susan M. Rivera
Flora Tassone
Flora Tassone
author_sort Reem R. Al Olaby
title Assessment of Molecular Measures in Non-FXTAS Male Premutation Carriers
title_short Assessment of Molecular Measures in Non-FXTAS Male Premutation Carriers
title_full Assessment of Molecular Measures in Non-FXTAS Male Premutation Carriers
title_fullStr Assessment of Molecular Measures in Non-FXTAS Male Premutation Carriers
title_full_unstemmed Assessment of Molecular Measures in Non-FXTAS Male Premutation Carriers
title_sort assessment of molecular measures in non-fxtas male premutation carriers
publisher Frontiers Media S.A.
series Frontiers in Genetics
issn 1664-8021
publishDate 2018-08-01
description Approximately 30–40% of male and 8–16% of female carriers of the Fragile X premutation will develop a neurodegenerative movement disorder characterized by intentional tremor, gait ataxia, autonomic dysfunction, cognitive decline, and Parkinsonism during their lifetime. At the molecular level, premutation carriers have increased expression levels of the FMR1 and the antisense FMR1 (ASFMR1) mRNAs. Both genes undergo alternative splicing giving rise to a number of different transcripts. Alteration in the alternative splicing process might be associated with FXTAS. In this study, we have investigated the correlation between objective measures of movement (balance and tremor using the CATSYS battery) and the expression of both the FMR1 and the ASFMR1 genes. In addition, we investigated whether their expression level and that of the ASFMR1 131 bp splice isoform could distinguish between premutation carriers with FXTAS and non-FXTAS premutation carriers. Confirming previous findings, the expression levels of transcripts at the FMR1 locus positively correlated with the CGG repeat number and significantly differentiated the premutation carriers from the control groups. Furthermore, premutation carriers with and without FXTAS, showed a significant difference in the expression level of the ASFMR1 131 bp splice isoform when compared to age and gender matched controls. However, there was no significant difference in the ASFMR1 131 bp splice isoform expression level when comparing premutation carriers with and without FXTAS. Finally, our results indicate significant group differences in CATSYS dominant hand reaction time and postural sway with eyes closed in premutation carriers without FXTAS compared to controls. In addition, a significant inverse association between the tremor intensity and the expression level of ASFMR1 131 bp splice isoform in premutation carriers compared to controls, was observed, suggesting a potential role in the pathogenesis of FXTAS.
topic FMR1
ASFMR1
transcription
premutation
FXTAS
CATSYS
url https://www.frontiersin.org/article/10.3389/fgene.2018.00302/full
work_keys_str_mv AT reemralolaby assessmentofmolecularmeasuresinnonfxtasmalepremutationcarriers
AT hiutungtang assessmentofmolecularmeasuresinnonfxtasmalepremutationcarriers
AT blythedurbinjohnson assessmentofmolecularmeasuresinnonfxtasmalepremutationcarriers
AT andreaschneider assessmentofmolecularmeasuresinnonfxtasmalepremutationcarriers
AT andreaschneider assessmentofmolecularmeasuresinnonfxtasmalepremutationcarriers
AT davidhessl assessmentofmolecularmeasuresinnonfxtasmalepremutationcarriers
AT davidhessl assessmentofmolecularmeasuresinnonfxtasmalepremutationcarriers
AT susanmrivera assessmentofmolecularmeasuresinnonfxtasmalepremutationcarriers
AT susanmrivera assessmentofmolecularmeasuresinnonfxtasmalepremutationcarriers
AT floratassone assessmentofmolecularmeasuresinnonfxtasmalepremutationcarriers
AT floratassone assessmentofmolecularmeasuresinnonfxtasmalepremutationcarriers
_version_ 1725513438995677184